A case of acute hyperammonemic encephalopathy after initiation of 5-fluorouracil chemotherapy
American Journal of Pharmacotherapy and Pharmaceutical Sciences · 2022
DOI: 10.25259/ajpps_16_2022 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Pharmacotherapy and Pharmaceutical Sciences, 2022. Verfasst von Timothy Daly und 6 weiteren Autor:innen. Die Arbeit nennt 9 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
5-fluorouracil is a chemotherapeutic agent that has been used for decades to treat a number of neoplasms. It has a number of adverse effects; however, we present a case of a seldom reported side effect in hyperammonemic encephalopathy that should be considered in patients presenting with altered mental status shortly after starting therapy.
Zitieren
APA
Daly, T., Prenatt, Z., Sagin, H., Wen, S., Shah, K., Proothi, S., & Hehar, P. (2022). A case of acute hyperammonemic encephalopathy after initiation of 5-fluorouracil chemotherapy. American Journal of Pharmacotherapy and Pharmaceutical Sciences. https://doi.org/10.25259/ajpps_16_2022
Vancouver
Daly T, Prenatt Z, Sagin H, Wen S, Shah K, Proothi S, et al. A case of acute hyperammonemic encephalopathy after initiation of 5-fluorouracil chemotherapy. American Journal of Pharmacotherapy and Pharmaceutical Sciences. 2022. doi:10.25259/ajpps_16_2022
BibTeX
@article{Daly2022,
author = {Daly, Timothy and Prenatt, Zarian and Sagin, Hannah and Wen, Sally and Shah, Kashyap and Proothi, Subhash and Hehar, Prabhdeep},
title = {A case of acute hyperammonemic encephalopathy after initiation of 5-fluorouracil chemotherapy},
journal = {American Journal of Pharmacotherapy and Pharmaceutical Sciences},
year = {2022},
doi = {10.25259/ajpps_16_2022}
}
EUVIMED